US HHS misses implementation deadline for transparency provision; drug, device firms concerned
This article was originally published in Clinica
A failure by the US Department of Health and Human Services to implement by its 1 October deadline procedures to explain what healthcare product firms will have to do to meet a forthcoming transparency provision has drawn concern from pharma and medtech companies.
You may also be interested in...
Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers.
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.